Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.54 |
| ▸ | KCNJ6 | P48051 | 5/20 | 0.49 |
| ▸ | KCNJ3 | P48549 | 5/20 | 0.49 |
| ▸ | KCNJ5 | P48544 | 4/20 | 0.49 |
| ▸ | RAF1 | P04049 | 7/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | ABL1 | P00519 | 6/20 | 0.44 |
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | SRC | P12931 | 4/20 | 0.44 |
| ▸ | AXL | P30530 | 4/20 | 0.44 |
| ▸ | PLK4 | O00444 | 3/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.44 |
| ▸ | LCK | P06239 | 3/20 | 0.44 |
| ▸ | FYN | P06241 | 3/20 | 0.44 |
| ▸ | LYN | P07948 | 3/20 | 0.44 |
| ▸ | RET | P07949 | 3/20 | 0.44 |
| ▸ | FRK | P42685 | 3/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.44 |
| ▸ | BLK | P51451 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080979 | 0.86 | BRAF (0.74) | BRAFMAPK14RAF1EPHX2ABL1 | |
| SCHEMBL2241149 | 0.84 | MAPK14 (0.62) | BRAFMAPK14KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2243108 | 0.84 | MAPK14 (0.59) | BRAFMAPK14KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2240648 | 0.83 | MAPK14 (0.58) | BRAFMAPK14KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2243426 | 0.83 | MAPK14 (0.62) | BRAFMAPK14KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2246436 | 0.83 | MAPK14 (0.59) | BRAFMAPK14KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2241234 | 0.82 | MAPK14 (0.58) | BRAFMAPK14KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2081581 | 0.79 | BRAF (0.63) | BRAFMAPK14RAF1ABL1KDR | |
| SCHEMBL2082382 | 0.79 | KCNJ6 (0.48) | BRAFKCNJ6KCNJ3KCNJ5RAF1 | |
| SCHEMBL2245642 | 0.77 | KCNJ6 (0.60) | BRAFMAPK14KCNJ6KCNJ3KCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | claimed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | claimed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | claimed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | claimed |
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | BRAF 4/4885MAPK14 128/4885KCNJ6 4192/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | BRAF 2/4885MAPK14 100/4885KCNJ6 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.